| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Edinburgh Breast Unit, Western General Hospital, Edinburgh, EH4 2XU, Scotland, United Kingdom [J. M. D., L. R., W. R. M.]; Department of Pathology, University of Edinburgh, Medical School, Edinburgh, Scotland, United Kingdom [C. B.]; and AstraZeneca, Alderley Park, Cheshire SK10 4TG, United Kingdom [M. S., G. H.-B.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONPATIENTS AND METHODSAnalysis of the ResultsRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSAnalysis of the ResultsRESULTSDISCUSSIONREFERENCES |
|---|
Currently, it is standard practice to offer adjuvant therapy to patients with surgically operable breast cancer. In cases of large, operable, locally advanced breast cancers, however, successful neoadjuvant (i.e., preoperative) systemic therapy has the advantage of downstaging primary tumors, thus permitting a more conservative approach that requires less extensive surgery (4) .
Although most studies have concentrated on chemotherapy as neoadjuvant treatment, a few groups have evaluated neoadjuvant endocrine therapy in hormone-sensitive, large, operable, locally advanced breast cancer (5, 6, 7) . Substantial reductions in tumor volume over a 3-month period have been recorded with tamoxifen (8) . The Edinburgh Breast Unit is indeed one group that has extensive experience of neoadjuvant systemic treatment for breast cancer (4) .
Postmenopausal women treated with either tamoxifen or an aromatase
inhibitor (either aminoglutethimide or 4-hydroxyandrostenedione) showed
a significant reduction in tumor size (5)
. Tamoxifen has
been used extensively as neoadjuvant therapy in locally advanced breast
cancer in elderly patients (i.e., 
75 years old; Ref.
7
). The amount of
ER3
protein expressed on
cancer cells is related to the response to endocrine therapy in primary
operable breast cancer; primary tumors with an ER concentration of <20
fmol/mg cytosol protein are unlikely to respond to endocrine therapy
(tamoxifen or an aromatase inhibitor) than those with higher ER values,
60% of which respond well (5)
.
The earlier aromatase inhibitors, aminoglutethimide and formestane, were not widely used in the neoadjuvant setting because of either their nonselectivity or the need for i.m. injection. In contrast, the new aromatase inhibitor anastrozole is a potent and selective nonsteroidal aromatase inhibitor and is given p.o. Used in postmenopausal women, this new-generation aromatase inhibitor is well tolerated and significantly reduces estrogen levels (9) . A combined analysis of two large, randomized trials in postmenopausal women with advanced breast cancer who had failed on tamoxifen therapy has shown that 1 mg of anastrozole significantly increases survival time compared with megestrol acetate at a mean follow-up of 31 months (10) . Additional trials with anastrozole include comparisons with tamoxifen in postmenopausal women with advanced breast cancer and comparisons with tamoxifen alone or the combination of anastrozole and tamoxifen as adjuvant treatment for early breast cancer in postmenopausal women.
It is possible that a more complete estrogen blockade using a newer selective aromatase inhibitor might result in greater tumor shrinkage than with tamoxifen, because tamoxifen is a weak or partial estrogen agonist in some organs (11) .
The aim of the current study was to investigate the effects of 1 mg of anastrozole (the clinically approved dose) and 10 mg of anastrozole once daily on tumor volume in the neoadjuvant setting in postmenopausal women with ER-rich, locally advanced or large (>3 cm), operable breast cancers. The inclusion of the 10-mg dose was for scientific reasons, to determine whether the data observed for 1 and 10 mg of anastrozole in the neoadjuvant setting mirrored that seen in the advanced breast cancer setting (10) and with respect to peripheral aromatase inhibition (9) .
|
PATIENTS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSAnalysis of the ResultsRESULTSDISCUSSIONREFERENCES |
|---|
50 years who had not menstruated in the last 12 months,
or women of any age with follicle-stimulating hormone levels >40
IU/liter. Diagnosis of breast carcinoma was confirmed using fine-needle
aspiration cytology. Only patients with operable breast cancers >3 cm
(T2, >3 cm; T3,
N0–1, M0) or locally
advanced breast cancers (T4b,
N0–1, M0) were included. Ethics committee approval was obtained, and the study was conducted in accordance with the Declaration of Helsinki. All of the patients in the study gave their written informed consent.
Patients were enrolled in the study between March 1997 and July 1998. Patients were screened for eligibility and to provide baseline assessments 4 weeks before randomization into the trial. This included a medical history, full physical examination, including a 12-lead electrocardiogram and laboratory determinations, an assessment of baseline evaluable disease clinically by calipers and ultrasound and also by mammogram, and a bone scan and chest X-ray to confirm the absence of overt metastases. For those assessments that could not be repeated at short intervals (e.g., bone scan, chest X-ray, mammogram), these were accepted if performed within 12 weeks before randomization. Exclusion criteria included drug-induced menopause; liver function tests more than three times the upper limit of the reference range; other abnormal laboratory test results that would place the patient at risk or confound the results of the study; patients with a history of systemic malignancy other than breast cancer, with the exception of basal or squamous cell carcinoma of the skin, or cancer of the cervix that had been satisfactorily controlled; and patients with an expected survival time of <3 months from the start of the study.
Patients were not allowed to receive any other systemic treatment for breast cancer in addition to their trial therapy. If any additional systemic therapy for breast cancer was required, trial therapy was withdrawn.
Study Design
This was a randomized (1:1), double blind, single-center study in
which patients received either 1 or 10 mg of anastrozole p.o. once
daily for 12 weeks. A total of 24 patients were to be recruited for
this trial. This number was based on feasibility rather than any formal
statistical technique.
An open wedge biopsy was performed removing approximately 1 g of tumor for confirmation of ER status and to obtain tissue for estrogen synthesis and uptake studies. Patients were reviewed for surgical wound healing after 10 days of treatment. Physical examinations (including tumor caliper assessments and ultrasound measurements) and safety and tolerability assessments were carried out at the visits at 4, 8, and 12 weeks.
At the last visit (week 12), a mammogram and, if it was believed clinically appropriate, a bone scan, chest X-ray, and electrocardiogram were also performed. Tumors were then excised by breast-conserving surgery or by mastectomy if appropriate. The excised tumor was measured in three dimensions to assess the actual tumor volume by pathology, and samples were removed for histology. The protocol required patients to be withdrawn from the study and undergo surgery earlier if there was any evidence of disease progression. Surgery also was performed earlier if a patient had responded well to the treatment (i.e., if the clinician predicted that there would be insufficient tissue remaining by the 12-week end point to provide adequate amounts of tumor tissue for assessment of all of the parameters).
Clinical Efficacy of Anastrozole
Measurement of Tumor Volume.
The percentage change in tumor volume (V) from baseline was
used to assess the response to treatment. Tumor volumes obtained using
caliper and mammography assessments were calculated by measuring the
average diameter (D) of the tumor (an average of four
diameters using calipers or two diameters with mammography) and using
the following formula (13)
:
 |
 |
Tolerability and Safety Assessments.
All of the adverse events were recorded, irrespective of their being
related to the trial therapy.
|
Analysis of the Results |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSAnalysis of the ResultsRESULTSDISCUSSIONREFERENCES |
|---|
For completeness, data on changes in the product of two diagonal clinical measurements 90° apart were calculated before and after treatment, and the percentage reduction was determined. This is the approach outlined by the UICC for measuring tumors.
Adverse event data were summarized by treatment received for all of the randomized patients who took trial treatment.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSAnalysis of the ResultsRESULTSDISCUSSIONREFERENCES |
|---|
;
the demography was comparable between the two treatment groups.
Twenty-one patients were classified as T2 at
baseline, two patients were T3, and one patient
was T4B (Table 1)
. Three patients had clinical
evidence of lymph node involvement. At the outset of the study, on the
basis of tumor volume compared with breast volume or disease stage, 17
patients would have required mastectomy according to our unit protocol.
The mean tumor volumes at baseline for the two treatment groups are
also given in Table 1
. One patient eligible for the study withdrew
because of adverse events (headaches, depression, and tiredness).
|
. With 10 mg/day of anastrozole, the
median reduction from baseline in tumor volume was calculated to be
99.6% using calipers (n = 11), 69.6% using ultrasound
(n = 11), and 69.3% using mammography measurements
(n = 11). For ultrasound assessments, the median
reduction from baseline when subjects receiving 1 and 10 mg anastrozole
were grouped together was 75.5%. The actual tumor volumes as measured
by the three assessment methods are also presented in Table 2
.
|
shows the individual percentage
reductions from baseline in tumor volumes of patients after 12 weeks of
anastrozole treatment. In all but two patients (patients 11 and 19),
all three of the methods of assessment showed a reduction in tumor
volume. Patient 11 showed an increase in tumor volume using ultrasound,
and patient 19 showed an increase in tumor volume using calipers.
|
. No patient showed a progression in
disease, regardless of the measurement used.
|
Measurement Techniques.
The tumor volumes calculated using calipers, ultrasound, and
mammography were all similar to the actual tumor volume measured by
pathology at week 12 (Table 4)
. The data
do suggest, however, that on the basis of descriptive assessment,
ultrasound is the most accurate measure of tumor volume because the
interquartile range (the difference between the presented lower and
upper quartiles) and the difference between the maximum and minimum
values were smaller with ultrasound measurements than with those of
calipers and mammography.
|
. Ultrasound measurements were closest
to the pathological volume, with no outliers being seen,
compared with calipers and mammography, in which four and one outliers
were seen, respectively.
|
. These groups equate to the UICC
criteria for complete response, partial response, and no change, but
because they were not maintained for 1 month (because surgery followed
the last assessment), they are not equivalent to UICC criteria.
|
. This study did not demonstrate any
consistent effect on nodal status, with the majority of patients (19 of
23) remaining clinically node negative throughout the study,
although in 7 of these cases nodal status was found to be positive on
pathological evaluation. The three patients who were
N1 at the start of treatment were pathologically
node-positive after therapy, although one was clinically downstaged to
N0. One patient had an increased clinical nodal
status from N0 to N1, but
pathological examination showed no nodal involvement.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSAnalysis of the ResultsRESULTSDISCUSSIONREFERENCES |
|---|
In clinical trials, both chemotherapy (many studies with different regimens) and endocrine therapy (tamoxifen and letrozole), when used as neoadjuvant therapy before surgery, have been shown to reduce tumor size (3 , 6 , 7 , 14 , 15) . Although chemotherapy can be used irrespective of estrogen status, studies of neoadjuvant therapy have demonstrated clearly that endocrine therapy is most effective in tumors that are ER-rich; hence, for the current study, this was a prerequisite to trial entry (5) . This small exploratory trial in selected patients with ER-rich tumors highlights the effectiveness of endocrine therapy in the form of the nonsteroidal aromatase inhibitors. Anastrozole was highly effective (in terms of breast conservation) in tumor downstaging in this selected group of postmenopausal women, thereby offering the clinician an additional tool for chemotherapy in the neoadjuvant setting. Generally, endocrine therapy is preferred in postmenopausal women because it is better tolerated than chemotherapy, and these data confirm that, in addition to good tolerability, anastrozole is highly effective in reducing tumor size. This study did not demonstrate any consistent effect on nodal status.
The role of neoadjuvant treatment in breast cancer remains to be fully determined. In line with data from other studies, this study confirms that neoadjuvant treatment can be useful in increasing the rate of breast conservation in women who would have previously required more radical surgery, including mastectomy. With the exception of the NSABP B-18 trial,4 however, there have been no trials of sufficient size and statistical power to determine the long-term outcome after neoadjuvant treatment. In the NSABP B-18 trial, there was no difference in disease-free survival or overall survival at a median of 5 years’ follow-up (16) .
Tumor volume is thought to be a useful indicator of response to treatment in patients with breast cancer. The results obtained with tumor volume in this study very closely reflect those with bidimensional measurements. However, a problem with bidimensional measurement is that it does not take into account tumor shape. In this study we chose to measure tumor volume by three methods—calipers, ultrasound, and mammography—during the 12-week treatment period and compared these measurements with final volume, as assessed by the pathologist after surgery.
The results obtained in the present study, based on a comparison of the interquartile ranges and scatter plots, indicate that ultrasound is the most accurate of the methods studied for assessing actual tumor volume. This is in agreement with the study by Forouhi et al. (13) , which concluded that ultrasound is the most practical and accurate method of measuring breast tumor volume and monitoring response to primary systemic treatment; however, this conclusion does require confirmation in larger studies specifically designed to address this issue. Other studies have investigated various methods of measuring breast tumor size, although not in the context of monitoring response to primary systemic treatment (17, 18, 19, 20) . In one study (17) , ultrasound was shown to be the most accurate technique of measuring tumor size compared with mammography and clinical measurements, but another study (18) described them as having the same degree of accuracy. However, other studies concluded that ultrasound is a useful adjunct to mammography in detecting tumor size, particularly in the diagnosis of breast cancer (19 , 20) . Ultrasound has the advantage that it is painless, easily performed, and has a low level of intraobserver error. It has now become our standard method of assessing response to primary systemic therapy.
In conclusion, our data from this small study suggest that anastrozole is highly effective as neoadjuvant therapy in postmenopausal women with ER-rich, large, operable breast cancers, as assessed by tumor volume. The study also showed that of the three noninvasive methods used to measure tumor volume, ultrasound is the most accurate. Additional studies with larger numbers of patients are required to confirm these findings. Future studies comparing anastrozole with tamoxifen as a neoadjuvant treatment are planned.
|
FOOTNOTES |
|---|
1 Supported by AstraZeneca, Alderley Park,
Cheshire, United Kingdom. 
2 To whom requests for reprints should be
addressed, at Edinburgh Breast Unit, Western General Hospital,
Edinburgh EH4 2XU, United Kingdom. Phone: 44-0-131-537-2643; Fax:
44-0-131-537-2653.
3 The abbreviations used are: ER, estrogen
receptor; UICC, Union International Contre le Cancer; NSABP, National
Surgical Adjuvant Breast and Bowel Project.
4 Patients with T1–3, N0
disease randomized either to surgery followed by four courses of
doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) or to four
courses of doxorubicin and cyclophosphamide followed by
surgery.
Received 11/ 9/99; revised 3/29/00; accepted 3/29/00.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSAnalysis of the ResultsRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  E. J. Macaskill, L. Renshaw, and J. M. Dixon Neoadjuvant Use of Hormonal Therapy in Elderly Patients with Early or Locally Advanced Hormone Receptor-Positive Breast Cancer Oncologist, November 1, 2006; 11(10): 1081 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Bulun, Z. Lin, G. Imir, S. Amin, M. Demura, B. Yilmaz, R. Martin, H. Utsunomiya, S. Thung, B. Gurates, et al. Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment Pharmacol. Rev., September 1, 2005; 57(3): 359 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. E. Smith, M. Dowsett, S. R. Ebbs, J. M. Dixon, A. Skene, J.-U. Blohmer, S. E. Ashley, S. Francis, I. Boeddinghaus, and G. Walsh Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial J. Clin. Oncol., August 1, 2005; 23(22): 5108 - 5116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cristofanilli, A. Gonzalez-Angulo, N. Sneige, S.-W. Kau, K. Broglio, R. L. Theriault, V. Valero, A. U. Buzdar, H. Kuerer, T. A. Buccholz, et al. Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes J. Clin. Oncol., January 1, 2005; 23(1): 41 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Plourde, E. O. Reiter, H.-C. Jou, P. E. Desrochers, S. D. Rubin, B. B. Bercu, F. B. Diamond Jr., and P. F. Backeljauw Safety and Efficacy of Anastrozole for the Treatment of Pubertal Gynecomastia: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4428 - 4433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial Clin. Cancer Res., July 15, 2004; 10(14): 4639 - 4644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Campos Aromatase Inhibitors for Breast Cancer in Postmenopausal Women Oncologist, April 1, 2004; 9(2): 126 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaufmann, G. von Minckwitz, R. Smith, V. Valero, L. Gianni, W. Eiermann, A. Howell, S. D. Costa, P. Beuzeboc, M. Untch, et al. International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations J. Clin. Oncol., July 1, 2003; 21(13): 2600 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Long, D. Jelovac, A. Thiantanawat, and A. M. Brodie The Effect of Second-Line Antiestrogen Therapy on Breast Tumor Growth after First-Line Treatment with the Aromatase Inhibitor Letrozole: Long-Term Studies Using the Intratumoral Aromatase Postmenopausal Breast Cancer Model Clin. Cancer Res., July 1, 2002; 8(7): 2378 - 2388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Morrow and W. Gradishar Recent developments: Breast cancer BMJ, February 16, 2002; 324(7334): 410 - 414. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
